The independent medical news service

Black men with localized prostate cancer fare better than their White counterparts after definitive radiotherapy, suggests a meta-analysis.

The addition of enzalutamide rather than a standard nonsteroidal anti-androgen to testosterone suppression is associated with worsening of some health-related quality of life function and symptom scores in men with metastatic hormone-sensitive prostate cancer, report the ENZAMET researchers.

Recovery of sexual function varies widely following radical prostatectomy at both the patient and surgeon level, but is not associated with surgeon case volume, US researchers report.

Postdiagnostic metformin or statin use may reduce the risk for death among people with advanced prostate cancer, suggests an analysis of US Veteran Health Administration data.

Around 10% of men with localized prostate cancer experience treatment-related regret but this rate varies by treatment modality and is mediated by posttreatment functional outcomes and patient expectations, study findings indicate.

Rates of prostate-specific antigen testing have increased significantly since 2017, following the publication of guidelines reversing a previous recommendation against routine prostate cancer screening in young men, US researchers report.